Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer (Q35958155)

11 August 2017

Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer (English)

1 reference

11 August 2017

1 reference

1

Zhaoxia Qu

1 reference

11 August 2017

6

Gutian Xiao

1 reference

11 August 2017

Fan Sun

2

1 reference

11 August 2017

Jingjiao Zhou

series ordinal

3

1 reference

11 August 2017

Liwen Li

series ordinal

4

1 reference

11 August 2017

Steven D Shapiro

series ordinal

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

29 June 2015

1 reference

11 August 2017

1 reference

11 August 2017

75

1 reference

11 August 2017

16

1 reference

11 August 2017

3209-3215

1 reference

Differential roles of STAT3 in the initiation and growth of lung cancer

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

The Role of STAT3 in Non-Small Cell Lung Cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

2 October 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Interleukin-6 and its receptor in cancer: implications for translational therapeutics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4537823

Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer

24 September 2018

1 reference

12 December 2020

[Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)]

1 reference

12 December 2020

Interleukin 6 and interleukin 1 receptor antagonist as early markers of complications after lung cancer surgery

1 reference

12 December 2020

Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?

1 reference

12 December 2020

10.1158/0008-5472.CAN-14-3042

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

26122841

1 reference